Pyrimethamine (2,4-diamino-5-p-chlorophenyl-6-ethyl-pyrimidine) induces apoptosis of freshly isolated human T lymphocytes, bypassing CD95/Fas molecule but involving its intrinsic pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 3, 2005, Pages 1046-1057

  Pierdominici, Marina ^a   Giammarioli, Anna Maria ^a   Gambardella, Lucrezia ^a   De Felice, Marco ^a   Quinti, Isabella ^b   Iacobini, Metello ^b   Carbonari, Maurizio ^b   Malorni, Walter ^a,c   Giovannetti, Antonello ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Department of Drug Research and Evaluation ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 8; FAS ANTIGEN; PYRIMETHAMINE; STEROID;

ANAMNESIS; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CELL ISOLATION; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; LABORATORY TEST; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; SPLENECTOMY; SPLENOMEGALY; T LYMPHOCYTE;

ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; CASPASE 10; CASPASE 8; CASPASES; CELLS, CULTURED; CHILD; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MEMBRANE POTENTIALS; MITOCHONDRIA; MODELS, BIOLOGICAL; PROPIDIUM; PYRIMETHAMINE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 27744547521     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.086736     Document Type: Article

References (34)

1. Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, La Grutta S, Correra A, and Notarangelo LD (1997) Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 89:902-909.
2. Bygbjerg IC (1985) Pyrimethamine-induced alterations in human lymphocytes in vitro. Mechanisms and reversal of the effect. Acta Pathol Microbiol Immunol Scand 93:183-188.
3. Bygbjerg IC, Odum N, and Theander TG (1986) Effect of pyrimethamine and sulphadoxine on human lymphocyte proliferation. Trans R Soc Trop Med Hyg 80:295-300.
4. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, et al. (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature (Lond) 419:395-399.
5. Cohen SB, Crawley JB, Kahan MC, Feldmann M, and Foxwell BM (1997) Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 92:1-5.
6. Cossarizza A, Franceschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A, and Malorni W (1995) Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res 220:232-240.
7. Debatin KM (1999) Activation of apoptosis pathways by anticancer drugs. Adv Exp Med Biol 457:237-244.
8. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, and Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649.
9. Ferri KF and Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3:E255-263.
10. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, and Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-946.
11. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, and Debatin KM (2001) Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20:1063-1075.
12. Hengartner MO (2000) The biochemistry of apoptosis. Nature (Lond) 407:770-776.
13. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D, et al. (1994) Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn community programs for clinical research on AIDS. J Infect Dis 169:384-394.
14. Kroemer G, Zamzami N, and Susin SA (1997) Mitochondrial control of apoptosis. Immunol Today 18:44-51.
15. Krysko O, De Ridder L, and Cornelissen M (2004) Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labeling technique. Apoptosis 9:495-500.
16. Lenardo MJ (2003) Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol Res 27:387-398.
17. Lopatin U, Yao X, Williams RK, Bleesing JJ, Dale JK, Wong D, Teruya-Feldstein J, Fritz S, Morrow MR, Fuss I, et al. (2001) Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 97:3161-3170.
18. Matarrese P, Cauda R, and Malorni W (2003) Activation-associated mitochondrial hyperpolarization hijacks T cells toward an apoptosis-sensitized phenotype. Cell Death Differ 10:609-611.
19. Pierdominici M, Mazzetta F, Caprini E, Marziali M, Digilio MC, Marino B, Aiuti A, Amati F, Russo G, Novelli G, et al. (2003) Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol 132:323-331.
20. Rieux-Laucat F, Fischer A, and Deist FL (2003) Cell-death signaling and human disease. Curr Opin Immunol 15, 325-331.
21. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, and de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (Wash DC) 268:1347-1349.
22. Schmitz I, Walczak H, Krammer PH, and Peter ME (1999) Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ 6:821-822.
23. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, and Daniel PT (2005) Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24:1904-1913.
24. Shi Y (2004) Caspase activation, inhibition and reactivation: a mechanistic view. Protein Sci 13:1979-1987.
25. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, and Strober W (1992) A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Investig 90:334-341.
26. Sprecher H, Barr HM, Slotky JI, Tzukerman M, Eytan GD, and Assaraf YG (1995) Alteration of mitochondrial gene expression and disruption of respiratory function by the lipophilic antifolate pyrimethamine in mammalian cells. J Biol Chem 270:20668-20676.
27. United States Public Health Service/Infectious Diseases Society of America (2000) 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 30 (Suppl 1):S29-S65.
28. van der Werff Ten Bosch J, Schotte P, Ferster A, Azzi N, Boehler T, Laurey G, Arola M, Demanet C, Beyaert R, et al. (2002) Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 117:176-188.
29. van der Werff ten Bosch JE, Demanet C, Balduck N, Bakkus MH, De Raeve H, Desprechins B, Otten J, and Thielemans K (1998) The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency. Br J Haematol 102:578-581.
30. Viora M, De Luca A, D'Ambrosio A, Antinori A, and Ortona E (1996) In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 40:1294-1297.
31. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, and Lenardo MJ (1999) Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98:47-58.
32. Weidekamm E, Plozza-Nottebrock H, Forgo I, and Dubach UC (1982) Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ 60:115-122.
33. Winstanley P (2001) Modern chemotherapeutic options for malaria. Lancet Infect Dis 1:242-250.
34. Wu J, Wilson J, He J, Xiang L, Schur PH, and Mountz JD (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Investig 98:1107-1113.